Home | Register | Login | Inquiries | Alerts | Sitemap |  


Advanced Search
JKM > Volume 46(2); 2025 > Article
Park, Park, Kim, and Lim: Gamitaeeumjowee-tang for Body Fat Loss in Female Patients with Sarcopenic Obesity: A Restrospective Chart Review

Abstract

Objectives

This study aims to evaluate the effects of Gamitaeeumjowee-tang on body weight and body composition in patients with sarcopenic obesity.

Methods

A retrospective chart review was conducted on 51 adults with sarcopenic obesity who registered for a weight loss program with Gamitaeeumjowee-tang for 12 weeks. Body weight, body composition including body fat mass and appendicular skeletal muscle mass index was measured before and after the intervention.

Results

A total of 51 patients were included in this study. After 12 weeks of treatment, the average weight loss rate was 6.52±3.4% (p<0.001) and body fat mass was significantly decreased by 15.85±8.4% (p<0.001). While fat free mass, skeletal muscle mass and appendicular skeletal muscle mass index showed no significant changes. The number of patients with sarcopenic obesity significantly decreased from 51 to 20 (60.8%, p<0.001). No serious adverse events were reported.

Conclusions

Gamitaeeumjowee-tang reduced body fat without compromising muscle mass in female patients with sarcopenic obesity. This suggests Gamitaeeumjowee-tang could be a promising treatment option, but further research including muscle strength assessments and additional interventions is needed.

Fig. 1
Flowchart of a retrospective chart review
jkm-46-2-63f1.gif
Table 1
Composition of Gamitaeeumjowee-tang
Ingredient Dose (g)/day
Ephedrae Herba 16.0–24.0
Rehmanniae Radix Preparat 8.0
Coicis Semen 8.0
Zingiberis Rhizoma Recens 4.0
Acori Gramineri Rhizoma 3.3
Zizyphi Semen 3.3
Alismatis Rhizoma 2.6
Scutellariae Radix 1.3
Schizandrae Fructus 1.3
Puerariae Radix 1.3
Asparagi Tuber 1.3
Angelicae Tenuissimae Radix 1.3
Longanae Arillus 1.3
Castanea Mollissima 1.3
Liriopis Tuber 1.3
Total Amount 55.6–63.6
Table 2
Baseline Characteristics
Variables Total (n=51)
Age (years) 37.08±11.0
Female (%) 51 (100%)
Body weight (kg) 56.76±3.0
ASMI (kg/m2) 5.49±0.1
BMI (kg/m2) 23.03±1.5
Skeletal muscle mass (kg) 18.24±1.0
Fat free mass (kg) 34.46±1.8
Body fat mass (kg) 22.30±2.6
Percentage of body fat (%) 39.21±3.1
Days of drug (day) 87.94±3.6

Data are expressed mean±standard deviation.

ASMI: appendicular skeletal muscle mass index, BMI: body mass index

Table 3
Body Weight and Body Composition Change after taking Gamitaeeumjowee-tang
Variables Initial value Final value Change
Body weight (kg) 56.76±3.0 53.06±3.4 3.70±1.0*
ASMI (kg/m2) 5.49±0.1 5.49±0.2 0.01±0.2
BMI (kg/m2) 23.03±1.5 21.52±1.5 1.52±0.8*
Skeletal muscle mass (kg) 18.24±1.0 18.15±1.1 0.09±0.6
Fat free mass (kg) 34.46±1.8 34.29±1.9 0.16±1.0
Body fat mass (kg) 22.30±2.6 18.77±2.9 3.53±1.9*
Percentage of body fat (%) 39.21±3.1 35.23±3.7 3.97±2.5*

Data are expressed mean±standard deviation.

ASMI: appendicular skeletal muscle mass index, BMI: body mass index

* P<0.001, paired t-test.

Table 4
Adverse Events Reported from 51 patients
Variables 2–6 weeks 10–14 weeks
Causality (WHO-UMC)
Possible 29(59.2) 8(50.0)
Unlikely 20(40.8) 8(50.0)
Conditional/unclassified 0(0.0) 0(0.0)
Total 49(100.0) 16(100.0)

Severity (CTCAE v5.0)
Mild (Grade 1) 48(98.0) 15(93.8)
Moderate (Grade 2) 1(2.0) 1(6.2)
Severe (Grade 3) 0
Total 49(100.0) 16(100.0)

Data are expressed in number (%).

WHO-UMC: World Health Organization-Uppsala Monitoring Centre, CTCAE: Common Terminology Criteria for Adverse Events.

Table 5
Adverse Events According to System Organ Classes
System-organ classes Symptom 2–6 weeks 10–14 weeks
Gastro-intestinal system disorders Constipation 2(4.1) 3(18.8)
Heartburn 2(4.1) 1(6.3)
Nausea 10(20.4) 2(12.5)

Autonomic nervous system disorders Dry mouth 5(10.2) 0(0.0)
Throat dry 2(4.1) 0(0.0)
Sweating increased 3(6.1) 0(0.0)
Palpitation 2(4.1) 1(6.3)

Central & peripheral nervous system disorders Dizziness 2(4.1) 0(0.0)
Tremor 3(6.1) 0(0.0)

Psychiatric disorders Insomnia 10(20.4) 4(25.0)
Body as a whole - general disorders Leg pain 0(0.0) 1(6.3)
Skin and appendages disorders Itching 1(0.0) 0(0.0)
Reproductive disorders, female Menstrual irregularity 2(4.1) 2(12.5)
Platelet, bleeding & clotting disorders Anal hemorrhage 1(2.0) 0(0.0)
Cardiovascular disorders, general Hypotension postural 1(2.0) 0(0.0)
Eye disorders blurred vision 1(2.0) 0(0.0)
Ear and Labyrinth disorders Tinnitus 1(2.0) 0(0.0)
Renal and urinary disorders Urinary frequency 1(2.0) 0(0.0)
Respiratory, thoracic and mediastinal disorders Throat irritation 0(0.0) 2(12.5)

Total 49(100.0) 16(100.0)

Data are expressed in number (%).

참고문헌

1. Gao, Q., Mei, F., Shang, Y., Hu, K., Chen, F., & Zhao, L., et al (2021). Global prevalence of sarcopenic obesity in older adults: A systematic review and meta-analysis. Clin Nutr, 40(7), 4633-4641. https://doi.org/10.1016/j.clnu.2021.06.009
crossref pmid

2. Atkins, J. L., & Wannamathee, S. G. (2020). Sarcopenic obesity in ageing: cardiovascular outcomes and mortality. Br J Nutr, 124(10), 1102-1113. https://doi.org/10.1017/S0007114520002172
crossref pmid

3. Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023). Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol (Lausanne), 14, 1185221. https://doi.org/10.3389/fendo.2023.1185221
crossref pmid pmc

4. Benz, E., Pinel, A., Guillet, C., Capel, F., Pereira, B., & De Antonio, M., et al (2024). Sarcopenia and Sarcopenic Obesity and Mortality Among Older People. JAMA network open, 7(3), e243604. https://doi.org/10.1001/jamanetworkopen.2024.3604
crossref pmid pmc

5. Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024). Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol, 20(5), 261-277. https://doi.org/10.1038/s41574-023-00943-z
crossref pmid pdf

6. Choi, H. A., & Park, K. M. (2016). Effects of Sarcopenic Obesity on Metabolic Syndrome in Korean Elders: Using Data from the Korea National Health and Nutrition Examination Survey (2008–2011). J Korean Acad Community Health Nurs, 27(3), 231-241. https://doi.org/10.12799/jkachn.2016.27.3.231
crossref pdf

7. Liu, C., Wong, P. Y., Chung, Y. L., Chow, S. K., Cheung, W. H., & Law, S. W., et al (2023). Deciphering the “obesity paradox” in the elderly: A systematic review and meta-analysis of sarcopenic obesity. Obes Rev, 24(2), e13534. https://doi.org/10.1111/obr.13534
crossref pmid pdf

8. Kim, T. N., Yang, S. J., Yoo, H. J., Lim, K. I., Kang, H. J., & Song, W., et al (2009). Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes (Lond), 33(8), 885-892. https://doi.org/10.1038/ijo.2009.130
crossref pmid pdf

9. Poggiogalle, E., Lubrano, C., Sergi, G., Coin, A., Gnessi, L., & Mariani, S., et al (2016). Sarcopenic Obesity and Metabolic Syndrome in Adult Caucasian Subjects. J Nutr Health Aging, 20(9), 958-963. https://doi.org/10.1007/s12603-015-0638-1
crossref pmid pdf

10. Zembura, M., & Matusik, P. (2022). Sarcopenic Obesity in Children and Adolescents: A Systematic Review. Front Endocrinol (Lausanne), 13, 914740. https://doi.org/10.3389/fendo.2022.914740
crossref pmid pmc

11. Schrager, M. A., Metter, E. J., Simonsick, E., Ble, A., Bandinelli, S., & Lauretani, F., et al (2007). Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol (1985), 102(3), 919-925. https://doi.org/10.1152/japplphysiol.00627.2006
crossref pmid pmc

12. Weiss, E. P., Jordan, R. C., Frese, E. M., Albert, S. G., & Villareal, D. T. (2017). Effects of Weight Loss on Lean Mass, Strength, Bone, and Aerobic Capacity. Med Sci Sports Exerc, 49(1), 206-217. https://doi.org/10.1249/MSS.0000000000001074
crossref pmid pmc

13. Park, Y. J., Cominguez, D. C., Kim, H. J., Jin, J. S., Koh, D. J., & Kim, S. Y., et al (2021). Therapeutic effects of Gambi-jung for the treatment of obesity. Biomed Pharmacother, 141, 111838. https://doi.org/10.1016/j.biopha.2021.111838
crossref pmid

14. Lee, Y. J., Kang, J. I., Kim, Y. H., Min, E. C., Lim, Y. W., & Kim, E. (2024). Gamitaeeumjowee-tang for Weight Loss in Post-Menopausal Obese Women: A Retrospective Chart Review. J Korean Med, 45(1), 64-78. https://doi.org/10.13048/jkm.24004
crossref

15. Zhou, X., Xing, B., He, G., Lyu, X., & Zeng, Y. (2018). The Effects of Electrical Acupuncture and Essential Amino Acid Supplementation on Sarcopenic Obesity in Male Older Adults: A Randomized Control Study. Obes Facts, 11(4), 327-334. https://doi.org/10.1159/000491797
crossref pmid pmc pdf

16. Park, M., Lim, Y. W., & Kim, E. (2024). Review on Weight Loss Interventions that Can Prevent Muscle Mass Loss in Sarcopenic Obesity. J Korean Med, 45(1), 79-98. https://doi.org/10.13048/jkm.24005
crossref

17. Lee, Y. B., Lee, A. R., Son, M. J., An, S. H., & Han, J. Y. (2024). Gamitaeeumjowee-tang for Patients with Class II or III Obesity: A Retrospective Chart Review. J Korean Med Obes Res, 24(2), 54-67. https://doi.org/10.15429/jkomor.2024.24.1.54


18. Lee, A. R., Son, M. J., An, S. H., Eom, Y. J., & Han, J. Y. (2024). Gamitaeeumjowee-tang for Elderly Female Patients with Overweight and Obesity: A Retrospective Chart Review. J Korean Med Obes Res, 24(2), 179-191. https://doi.org/10.15429/jkomor.2024.24.2.179
crossref

19. Hwang, B., Lim, J. Y., Lee, J., Choi, N. K., Ahn, Y. O., & Park, B. J. (2012). Prevalence rate and associated factors of sarcopenic obesity in korean elderly population. J Korean Med Sci, 27(7), 748-755. https://doi.org/10.3346/jkms.2012.27.7.748
crossref pmid pmc pdf

20. Hwang, J. (2024). Sarcopenic Obesity Frequency and Associated Risk Factors in Young Korean Women: A Comprehensive Cross-Sectional Analysis. KSPM, 19, 43-51. https://doi.org/10.13066/kspm.2024.19.1.43
crossref

21. Kim, K. K., Haam, J. H., Kim, B. T., Kim, E. M., Park, J. H., & Rhee, S. Y., et al (2023). Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr, 32(1), 1-24. https://doi.org/10.7570/jomes23016
crossref pmid pmc

22. Camajani, E., Persichetti, A., Watanabe, M., Contini, S., Vari, M., & Di Bernardo, S., et al (2022). Whey Protein, L-Leucine and Vitamin D Supplementation for Preserving Lean Mass during a Low-Calorie Diet in Sarcopenic Obese Women. Nutrients, 14(9), 1884. https://doi.org/10.3390/nu14091884
crossref pmid pmc

23. Sammarco, R., Marra, M., Di Guglielmo, M. L., Naccarato, M., Contaldo, F., & Poggiogalle, E., et al (2017). Evaluation of Hypocaloric Diet With Protein Supplementation in Middle-Aged Sarcopenic Obese Women: A Pilot Study. Obes facts, 10(3), 160-167. https://doi.org/10.1159/000468153
crossref pmid pmc pdf

24. Nabuco, H. C. G., Tomeleri, C. M., Fernandes, R. R., Sugihara, P., Cavalcante, E. F., & Cunha, P. M., et al (2019). Effect of whey protein supplementation combined with resistance training on body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers in older women with sarcopenic obesity: A randomized, double-blind, placebo-controlled trial. Clin Nutr ESPEN, 32, 88-95. https://doi.org/10.1016/j.clnesp.2019.04.007
pmid

25. Kim, S., Seok, J., & Ok, J. M. (2024). Application of Korean Herbal Medicine for Body Fat Loss in Adults with Normal Weight Obesity: A Retrospective Chart Review. Korean J Subhealth Med, 5(1), 15-26. https://doi.org/10.37928/kjsm.2024.5.1.15
crossref

26. Oliveros, E., Somers, V. K., Sochor, O., Goel, K., & Lopez-Jimenez, F. (2014). The concept of normal weight obesity. Prog Cardiovasc Dis, 56(4), 426-433. https://doi.org/10.1016/j.pcad.2013.10.003
crossref pmid

27. De Lorenzo, A., Pellegrini, M., Gualtieri, P., Itani, L., El Ghoch, M., & Di Renzo, L. (2022). The Risk of Sarcopenia among Adults with Normal-Weight Obesity in a Nutritional Management Setting. Nutrients, 14(24), 5295. https://doi.org/10.3390/nu14245295
crossref pmid pmc

28. Yoon, N. R., Yoo, Y. J., Kim, M., Kim, S. Y., Lim, Y. W., & Lim, H. H., et al (2018). Analysis of Adverse Events in Weight Loss Program in Combination with ‘Gamitaeeum jowee-Tang’ and Low-Calorie Diet. J Korean Med Obes Res, 18(1), 1-9. https://doi.org/10.15429/jkomor.2018.18.1.1


29. Christensen, P., Bliddal, H., Riecke, B. F., Leeds, A. R., Astrup, A., & Christensen, R. (2011). Comparison of a low-energy diet and a very low-energy diet in sedentary obese individuals: a pragmatic randomized controlled trial. Clin Obes, 1(1), 31-40. https://doi.org/10.1111/j.1758-8111.2011.00006.x
crossref pmid pdf

30. Sergi, G., De Rui, M., Stubbs, B., Veronese, N., & Manzato, E. (2017). Measurement of lean body mass using bioelectrical impedance analysis: a consideration of the pros and cons. Aging Clin Exp Res, 29(4), 591-597. https://doi.org/10.1007/s40520-016-0622-6
crossref pmid pdf

31. Chen, L. K., Woo, J., Assantachai, P., Auyeung, T. W., Chou, M. Y., & Iijima, K., et al (2020). Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc, 21(3), 300-307.e2. https://doi.org/10.1016/j.jamda.2019.12.012
crossref pmid

Editorial office contact information
3F, #26-27 Gayang-dong, Gangseo-gu Seoul, 157-200 Seoul, Korea
The Society of Korean Medicine
Tel : +82-2-2658-3627   Fax : +82-2-2658-3631   E-mail : skom1953.journal@gmail.com
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Developed in M2PI